liu.seSök publikationer i DiVA
Ändra sökning
Avgränsa sökresultatet
1 - 4 av 4
RefereraExporteraLänk till träfflistan
Permanent länk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Träffar per sida
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sortering
  • Standard (Relevans)
  • Författare A-Ö
  • Författare Ö-A
  • Titel A-Ö
  • Titel Ö-A
  • Publikationstyp A-Ö
  • Publikationstyp Ö-A
  • Äldst först
  • Nyast först
  • Skapad (Äldst först)
  • Skapad (Nyast först)
  • Senast uppdaterad (Äldst först)
  • Senast uppdaterad (Nyast först)
  • Disputationsdatum (tidigaste först)
  • Disputationsdatum (senaste först)
  • Standard (Relevans)
  • Författare A-Ö
  • Författare Ö-A
  • Titel A-Ö
  • Titel Ö-A
  • Publikationstyp A-Ö
  • Publikationstyp Ö-A
  • Äldst först
  • Nyast först
  • Skapad (Äldst först)
  • Skapad (Nyast först)
  • Senast uppdaterad (Äldst först)
  • Senast uppdaterad (Nyast först)
  • Disputationsdatum (tidigaste först)
  • Disputationsdatum (senaste först)
Markera
Maxantalet träffar du kan exportera från sökgränssnittet är 250. Vid större uttag använd dig av utsökningar.
  • 1.
    Dahlberg, Johanna
    et al.
    Linköpings universitet, Institutionen för klinisk och experimentell medicin. Linköpings universitet, Hälsouniversitetet.
    Karlsson, Katarina
    Linköpings universitet, Institutionen för medicin och hälsa, Omvårdnad. Linköpings universitet, Hälsouniversitetet.
    Pelling, Staffan
    Linköpings universitet, Institutionen för medicin och hälsa, Omvårdnad. Linköpings universitet, Hälsouniversitetet.
    Interprofessional undergraduate student teams performe quality improvement work in clinical settings2010Konferensbidrag (Övrig (populärvetenskap, debatt, mm))
    Abstract [en]

    To be powerful, improvement of quality and safety (IQS) should be performed by all involved professionals in cooperation. Here we describe how we have designed and implemented improvement of quality and safety as a recurring interprofessional learning objective to all programmes at The Faculty of Health Sciences (FHS), Linköping University, Sweden. This initiative was strongly argued and implemented in close collaboration with the County Council of Östergötland (CCO), the main provider of health care in the region.

     

    The Faculty of Health Sciences has experience of interprofessional education since more than 20 years, which we and external evaluations have found to be successful. In addition, all our educational programs are based on Problem-Based Learning (PBL) throughout the whole curricula. The procedures for IQS-work have great similarities to the processes of PBL, and the research process, hence, the implementation of IQS are easily acknowledged by the students, faculty and clinical staff.

     

    Since 2008, students from all our undergraduate programs learn IQS-methodology during their first semester as individual projects, as part of the first module of interprofessional learning. Now the partnership with the CCO has offered opportunities to include practice of IQS in clinical settings. In close collaboration with the staff from primary health care centers or clinical wards, interprofessional student teams have identified areas of quality and safety improvement. These were e.g. i) accessibility to acute care, ii) routines regarding the discharge process at a surgery ward, or iii) hygiene aspects in primary health care The suggested conclusions and interventions were received, discussed and developed at the clinics.

  • 2.
    Edelbring, Samuel
    et al.
    Linköpings universitet, Institutionen för medicin och hälsa, Avdelningen för samhällsmedicin. Linköpings universitet, Medicinska fakulteten. Karolinska Institutet.
    Karlsson, Katarina
    Linköpings universitet, Institutionen för medicin och hälsa, Avdelningen för omvårdnad. Linköpings universitet, Medicinska fakulteten.
    Meyer, Frida
    Linköpings universitet, Institutionen för medicin och hälsa. Linköpings universitet, Medicinska fakulteten.
    Tamás, Éva
    Linköpings universitet, Institutionen för medicin och hälsa, Avdelningen för kardiovaskulär medicin. Linköpings universitet, Medicinska fakulteten. Region Östergötland, Hjärt- och Medicincentrum, Thorax-kärlkliniken i Östergötland.
    Utvärdering av IPL-simulering på Clinicum: Simuleringsdag ”Akuta situationer” för sistaårsstudenter från sjuksköterske- och läkarprogrammen HT 20162017Rapport (Övrigt vetenskapligt)
    Abstract [sv]

    En gemensam simuleringsdag för sjuksköterske- och läkarstudenter har utvärderats och diskuteras här i relation till interprofessionellt lärande och simuleringsbaserat lärande.

    IPL-simuleringen kännetecknas av ett starkt studentengagemang och upplevs som mycket relevant och kliniskt autentisk. Den simuleringsbaserade satsningen är alltså fortsatt aktuell och har utvecklats till en hög nivå med relevans för lärande och klinisk förberedelse. Innehållet rör såväl kliniska som team­relaterade kunskaper och kompetenser. Simulering som undervisningsform uppskattas högt och simulerings­instruktörens bidrag till lärandet lyfts fram. Ambitionsnivån kan ytterligare höjas på några punkter. Kurskamraternas bidrag i lärandet kan ytterligare stärkas, likaså omvårdnads­innehållet i scenarierna.

    IPL-mål adresseras i aktiviteten, i synnerhet ökar teamsamverkan progressivt under dagen. Det inter­professionella lärandet kan stärkas ännu mer  genom att linjera tydligare med övriga IPL-moment samt knyta an till de uttalade IPL-curriculum-målen.

  • 3.
    Walsh, S.H.
    et al.
    Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden.
    Grabowski, P.
    Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
    Berglund, M.
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden.
    Thunberg, U.
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden.
    Thorselius, M.
    Thorsélius, M., Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden.
    Tobin, G.
    Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden.
    Aleskog, A.
    Åleskog, A., Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
    Karlsson, Katarina
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för medicin och hälsa, Omvårdnad.
    Sundstrom, C.
    Sundström, C., Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden.
    Laurell, A.
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden.
    Enblad, G.
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden.
    Rosenquist, R.
    Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden.
    Roos, G.
    Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden, Department of Medical Biosciences, Umeå University, SE-90187 Umeå, Sweden.
    Telomere length and correlation with histopathogenesis in B-cell leukemias/lymphomas2007Ingår i: European Journal of Haematology, ISSN 0902-4441, E-ISSN 1600-0609, Vol. 78, nr 4, s. 283-289Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Telomere length was recently reported to correlate with cellular origin of B-cell malignancies in relation to the germinal center (GC). In this report, we measured telomere length by quantitative-PCR in 223 B-cell lymphomas/leukemias and correlated results with immunoglobulin (Ig) mutation status and immunostainings for GC/non-GC subtypes of diffuse large B-cell lymphoma (DLBCL). Shortest telomeres were found in Ig-unmutated chronic lymphocytic leukemia (CLL) [median telomere to single copy gene value (T/S) 0.33], differing significantly to Ig-mutated CLL (0.63). Contrary to this, mantle cell lymphomas (MCLs) exhibited similar telomere lengths regardless of Ig mutation status (0.47). Telomere length differed significantly between GC-like (0.73) and non-GC-like DLBCLs (0.43), and follicular lymphomas (FLs) had shorter telomeres (0.53) than GC-DLBCL. Hairy cell leukemias, which display Ig gene intraclonal heterogeneity, had longer telomeres (0.62) than FLs and non-GC-DLBCL, but shorter than GC-DLBCL. We conclude that although DLBCL and CLL subsets can be clearly distinguished, telomere length reflects many parameters and may not simply correlate with GC-related origin. © 2007 The Authors.

  • 4.
    Wilking, N.
    et al.
    Department of Oncology, Karolinska Institutet, Stockholm, Sweden, Radiumhemmet Karolinska Hospital, Stockholm, Sweden.
    Lidbrink, E.
    Radiumhemmet, Karolinska Institutet and University Hospital, Solna, S-171 76 Stockholm, Sweden.
    Wiklund, T.
    Roche OY, Espoo, Finland, Department of Oncology, University Hospital, Helsinki, Finland.
    Erikstein, B.
    Southern Norway Regional Health Authority, Skien, Norway, The Norwegian Radiumhospital, Oslo, Norway.
    Lindman, H.
    Department of Oncology, Akademiska Hospital, Uppsala, Sweden.
    Malmstrom, P.
    Malmström, P., Department of Oncology, University Hospital, Lund, Sweden.
    Kellokumpu-Lehtinen, P.
    Department of Oncology, Tampere University, University Hospital, Tampere, Finland.
    Bengtsson, N.-O.
    Department of Oncology, University Hospital, Umeå, Sweden.
    Söderlund, G.
    Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Onkologiska kliniken US.
    Anker, G.
    Department of Oncology, Haukeland University Hospital, Bergen, Norway, Department of Oncology, Haukeland Hospital, Bergen, Norway.
    Wist, E.
    Department of Oncology, Ullevål University Hospital and Faculty of Medicine, University of Oslo, Oslo, Norway, Department of Oncology, Regional Hospital, Tromsø, Norway.
    Ottosson, S.
    Department of Oncology, NÄL, Trollhättan, Sweden.
    Salminen, E.
    Department of Oncology, Turku University Hospital, Turku, Finland.
    Ljungman, P.
    Haematology Centre, Karolinska University Hospital, Stockholm, Sweden, Department of Hematology, Huddinge Hospital, Stockholm, Sweden.
    Holte, H.
    Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway, Hematology Section, The Norwegian Radiumhospital, Oslo, Norway.
    Nilsson, J.
    Trial Form Support AB, Stockholm, Sweden.
    Blomqvist, C.
    Department of Oncology, University Hospital, Helsinki, Finland.
    Bergh, J.
    Department of Oncology, Karolinska Institutet, Stockholm, Sweden, Radiumhemmet, Karolinska Institutet and University Hospital, Solna, S-171 76 Stockholm, Sweden, Radiumhemmet Karolinska Hospital, Stockholm, Sweden.
    Hoglund, M.
    Höglund, M., Department of Hematology, University Hospital, Uppsala, Sweden.
    Bengtsson, M.
    Department of Clinical Immunology, University Hospital, Uppsala, Sweden.
    Gruber, A.
    Department of Hematology, Karolinska Hospital, Stockholm, Sweden.
    Fornander, T.
    Department of Oncology, Södersjukhuset,, Stockholm, Sweden.
    Petterson-Skold, D.
    Petterson-Sköld, D., Department of Oncology, Danderyd Hospital, Stockholm, Sweden.
    Lofvenberg, E.
    Löfvenberg, E., Department of Hematology, University Hospital, Umeå, Sweden.
    Villman, K.
    Department of Oncology, Örebro Hospital, Örebro, Sweden.
    Karlsson, Katarina
    Linköpings universitet, Hälsouniversitetet. Linköpings universitet, Institutionen för medicin och hälsa, Omvårdnad.
    Hultborn, R.
    Department of Oncology, Sahlgrenska Hospital, Göteborg, Sweden.
    Ottoson, S.
    Department of Oncology, Sahlgrenska Hospital, Göteborg, Sweden.
    Mattson, J.
    Department of Surgery, Sahlgrenska Hospital, Göteborg, Sweden.
    Jansson, S.
    Department of Surgery, Sahlgrenska Hospital, Göteborg, Sweden.
    Braide, I.
    Department of Hematology, Sahlgrenska Hospital, Göteborg, Sweden.
    Carlsson, G.
    Department of Oncology, Östra Hospital, Göteborg, Sweden.
    Rodjer, S.
    Rödjer, S., Department of Hematology, Östra Hospital, Göteborg, Sweden.
    Sallerfors, B.
    Department of Hematology, University Hospital, Lund, Sweden.
    Ahlgren, J.
    Department of Oncology, Gävle Hospital, Gävle, Sweden.
    Gawelin, A.
    Department of Oncology, Gävle Hospital, Gävle, Sweden.
    Solderberg, M.
    Sölderberg, M., Department of Oncology, Karlstad Hospital, Karlstad, Sweden.
    Hansen, J.
    Department of Oncology, Västerås Hospital, Västerås, Sweden.
    Stenstam, B.
    Department of Oncology, Mälarsjukhuset, Eskilstuna, Sweden.
    Svensson, J.-H.
    Mälarsjukhuset Eskilstuna of Oncology, Borås Hospital, Borås, Sweden.
    Norberg, B.
    Department of Oncology, Ryhov Hospital, Jönköping, Sweden.
    Kvalheim, G.
    Department of Medicine, The Norwegian Radiumhospital, Oslo, Norway.
    Sommer, H.H.
    Department of Oncology, Ullevål Hospital, Oslo, Norway.
    Tangen, J.M.
    Department of Hematology, Ullevål Hospital, Oslo, Norway.
    Lundgren, S.
    Department of Oncology, Regional Hospital, Trondheim, Norway.
    Remes, K.
    Department of Internal Medicine, University Hospital, Turku, Finland.
    Lehtinen, M.
    Department of Clinical Chemistry, Division of Hematology, University Hospital, Tampere, Finland.
    Koivinen, E.
    Department of Clinical Chemistry, Division of Hematology, University Hospital, Tampere, Finland.
    Turpeenniemi-Hujanen, T.
    Department of Oncology, Oulu University Hospital, Oulu, Finland.
    Kuittinen, O.
    Department of Oncology, Oulu University Hospital, Oulu, Finland.
    Voutilainen, L.
    Department of Oncology, Kuopio University Hospital, Kuopio, Finland.
    Mirza, M.R.
    Department of Oncology, University Hospital, Odense, Denmark.
    Rose, C.
    Department of Oncology, University Hospital, Odense, Denmark.
    Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy2007Ingår i: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 18, nr 4, s. 694-700Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Background: The purpose was to investigate adjuvant marrow-supportive high-dose chemotherapy compared with an equitoxicity-tailored comparator arm. Patients and methods: Five hundred and twenty-five women below theage of 60 years with operated high-risk primary breast cancer were randomised to nine cycles of granulocyte colony-stimulating factor supported and individually tailored FEC (5-fluorouracil, epirubicin, cyclophosphamide), (n = 251) or standard FEC followed by marrow-supported high-dose therapy with CTCb (cyclophosphamide, thiotepa, carboplatin) therapy (n = 274), followed by locoregional radiotherapy and tamoxifen for 5 years. Results: There were 104 breast cancer relapses in the tailored FEC group versus 139 in the CTCb group (double triangular method by Whitehead, P = 0.046), with a median follow-up of all included patients of 60.8 months. The event-free survival demonstrated 121 and 150 events in the tailored FEC- and CTCb group, respectively [P = 0.074, hazard ratio (HR) 0.804, 95% confidence interval (CI) 0.633-1.022]. Ten patients in the tailored FEC regimen developed acute myeloid leukaemia (AML)/myelodysplasia (MDS). One hundred deaths occurred in the tailored FEC group and 121 in the CTCb group (P = 0.287, HR 0.866, 95% CI 0.665-1.129). Conclusion: The update of this study shows an improved outcome linked to the tailored FEC treatment in relation to breast cancer relapse, but also an increased incidence of AML/MDS. © 2007 Oxford University Press.

1 - 4 av 4
RefereraExporteraLänk till träfflistan
Permanent länk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf